Cargando…

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

Mostrar otras versiones (1)

BACKGROUND: Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time. OBJECTIVE: To determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals. METHODS: Anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Israel, Ariel, Shenhar, Yotam, Green, Ilan, Merzon, Eugene, Golan-Cohen, Avivit, Schäffer, Alejandro A, Ruppin, Eytan, Vinker, Shlomo, Magen, Eli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404903/ https://www.ncbi.nlm.nih.gov/pubmed/34462761 http://dx.doi.org/10.1101/2021.08.19.21262111

Ejemplares similares

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
por: Israel, Ariel, et al.
Publicado: (2021)

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort
por: Israel, Ariel, et al.
Publicado: (2021)

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
por: Israel, Ariel, et al.
Publicado: (2021)

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination
por: Israel, Ariel, et al.
Publicado: (2022)

Predicting COVID-19 severity using major risk factors and received vaccines
por: Israel, Ariel, et al.
Publicado: (2022)

A Calculator for COVID-19 Severity Prediction Based on Patient Risk Factors and Number of Vaccines Received
por: Israel, Ariel, et al.
Publicado: (2022)

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Long-Term Risk of Immune-Related diseases
por: Israel, Ariel, et al.
Publicado: (2023)

Glucose-6-phosphate dehydrogenase deficiency and long-term risk of immune-related disorders
por: Israel, Ariel, et al.
Publicado: (2023)

Selective IgA deficiency and COVID-19
por: Magen, Eli, et al.
Publicado: (2023)

COVID-19 Susceptibility in Bronchial Asthma
por: Green, Ilan, et al.
Publicado: (2021)

A higher frequency of physical activity is associated with reduced rates of SARS-CoV-2 infection
por: Green, Ilan, et al.
Publicado: (2022)

Author’s reply to comment on: A higher frequency of physical activity is associated with reduced rates of SARS-CoV-2 infection
por: Green, Ilan, et al.
Publicado: (2023)

The Association of Weight Reduction and Other Variables after Bariatric Surgery with the Likelihood of SARS-CoV-2 Infection
por: Frish, Noam, et al.
Publicado: (2023)

The Association between Previous Antibiotic Consumption and SARS-CoV-2 Infection: A Population-Based Case-Control Study
por: Dugot, Matan, et al.
Publicado: (2023)

The Association of Previous Vaccination with Live-Attenuated Varicella Zoster Vaccine and COVID-19 Positivity: An Israeli Population-Based Study
por: Merzon, Eugene, et al.
Publicado: (2022)

Higher rates of allergies, autoimmune diseases and low-grade inflammation markers in treatment-resistant major depression
por: Lauden, Ari, et al.
Publicado: (2021)

The Effect of Antibiotic Treatment of Early Childhood Shigellosis on Long-Term Prevalence of Attention Deficit/Hyperactivity Disorder
por: Sadaka, Yair, et al.
Publicado: (2021)

Patient-level predictors of temporal regularity of primary care visits
por: Rose, Adam J., et al.
Publicado: (2023)

The Association between Somatotropin Therapy and the Risk of SARS-CoV-2 Infection in Children with Short Stature: A Population-Based Cross-Sectional Study
por: Brill, Gherta, et al.
Publicado: (2022)

ADHD as a Risk Factor for Infection With Covid-19
por: Merzon, Eugene, et al.
Publicado: (2020)

Greater temporal regularity of primary care visits was associated with reduced hospitalizations and mortality, even after controlling for continuity of care
por: Khazen, Maram, et al.
Publicado: (2023)

The efficacy of single pharmacist medication review among type II diabetic patients who take six chronic medications or more: a case–control study
por: Harmatz, Danielle, et al.
Publicado: (2022)

Clinical and Socio-Demographic Variables Associated with the Diagnosis of Long COVID Syndrome in Youth: A Population-Based Study
por: Merzon, Eugene, et al.
Publicado: (2022)

Early Childhood Shigellosis and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study with a Prolonged Follow-up
por: Merzon, Eugene, et al.
Publicado: (2020)

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis
por: Magen, Eli, et al.
Publicado: (2022)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
por: Jo, Dong-Ho, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Ferrari, Davide, et al.
Publicado: (2021)

Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Antibody titers among healthcare workers for coronavirus disease 2019 at 6 months after BNT162b2 vaccination
por: Kurashima, Kazuyoshi, et al.
Publicado: (2022)

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
por: Herzberg, Jonas, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults
por: Eliakim-Raz, Noa, et al.
Publicado: (2022)

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
por: Izumo, Takehiro, et al.
Publicado: (2021)

BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study
por: Rahav, Galia, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
por: Álvarez-Díaz, Diego A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sh93c213dt61tnofrs64lg360d